Your session is about to expire
← Back to Search
Study Summary
This trial is testing if a new vaccine is safe and effective for people with weakened immune systems.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 2431 Patients • NCT04440163Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a condition that causes inflammation or an overactive immune system, such as multiple sclerosis, optic neuritis or uveitis.You have a medical or mental condition that could make it risky for you to participate in the study, or you have had thoughts of hurting yourself in the past year.You have already received a vaccine for meningococcal serogroup B in the past.You have a serious neurological disorder or a history of seizures, except for simple febrile seizures.You are currently taking antibiotics for a long period of time.You have a higher risk of getting meningococcal disease because of a condition that affects your immune system or certain blood disorders.You have participated in another study that involves testing new drugs within the past 28 days, or plan to participate in one during the current study.
- Group 1: Single Arm
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the FDA approved Trumenba for use?
"Trumenba has been approved for use, so its safety rating is a 3 on our scale."
Is this research unique in its approach?
"Trumenba's initial clinical trial, held in 2021 and sponsored by Sanofi Pasteur, was a success that enabled the drug to move from Phase 1 & 2 into approval. Since then, 3 additional studies have been carried out across 21 cities and 6 countries with 1800 participants taking part collectively."
How many participants are enrolled in this medical study?
"This study is no longer looking for patients. It was originally published on August 18th 2021, and the last update came through October 10th 2022. Alternately, there are currently two medical trials recruiting participants to receive meningococcal vaccines and another three seeking volunteers for Trumenba administration."
Are there any vacancies remaining for participants in this research endeavor?
"After consulting clinicaltrials.gov, it appears that this research project has halted its participant recruitment for now after originally being posted on August 18th 2021 and last revised on October 10th 2022. Nevertheless, there are 5 other medical experiments presently recruiting patients to participate in their respective trials."
Share this study with friends
Copy Link
Messenger